<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521636</url>
  </required_header>
  <id_info>
    <org_study_id>10-038</org_study_id>
    <nct_id>NCT02521636</nct_id>
  </id_info>
  <brief_title>Clinical Trial Assessing the Value of an Antibiotic Protocol Guided by Serum Procalcitonin in Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Intensive Care</brief_title>
  <acronym>BPCTréa</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose to conduct a prospective, randomized, controlled, multicenter assessing&#xD;
      the interests of an antibiotic protocol guided by serum procalcitonin (PCT) on morbidity and&#xD;
      mortality in patients with chronic obstructive pulmonary disease (COPD) hospitalized in&#xD;
      intensive care unit (ICU) for acute exacerbation with or without associated pneumonia. The&#xD;
      main objective is to show in patients hospitalized in intensive care for acute exacerbation&#xD;
      of COPD with or without pneumonia, safety, defined as a lack of difference in mortality at 3&#xD;
      months, an antibiotic strategy guided by the PCT in the ICU.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Anibiotic therapy guided with actual french recommandations</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Guided by the antibiotic 2006 recommendations of the French consensus conference on anti-infective therapy of respiratory tract infections in low immuno-competent adult.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anibiotic therapy guided with serum PCT value</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guided antibiotic therapy serum PCT at admission, revalued at day 1, day 3 and day 6 as long as PCT is not less than 0.1 ng / mL:&#xD;
PCT &lt;0.1 ng / mL: no antibiotics&#xD;
0.1 &lt;PCT &lt;0.25 ng / mL: antibiotic advised&#xD;
PCT&gt; 0.25 ng / mL: highly recommended antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antibiotic therapy randomization</intervention_name>
    <arm_group_label>Anibiotic therapy guided with actual french recommandations</arm_group_label>
    <arm_group_label>Anibiotic therapy guided with serum PCT value</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum PCT dosage</intervention_name>
    <arm_group_label>Anibiotic therapy guided with serum PCT value</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients over 18 years&#xD;
&#xD;
          -  Documented or suspected clinically COPD according to the criteria of GOLD&#xD;
&#xD;
          -  In acute exacerbation&#xD;
&#xD;
          -  Suspect of lower respiratory tract infection&#xD;
&#xD;
          -  With or without pulmonary criteria defined as the presence of a radiological&#xD;
             infiltrates consistent with an infectious site and associated with one or more of the&#xD;
             following items: dyspnea, cough, sputum, fever above 38 ° C, fireplace clinical&#xD;
             auscultation, higher leukocytosis at 10,000 / mm³ or leukopenia below 4000 / mm³&#xD;
&#xD;
          -  Admitted to the hospital for less than 48 hours&#xD;
&#xD;
          -  ICU Admission&#xD;
&#xD;
          -  Informed Consent signed by the patient or his representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other than acute exacerbation etiology with or without pulmonary disease as suspected&#xD;
             cause of ICU admission&#xD;
&#xD;
          -  Patient immunocompromised neutropenia neutrophil count below 500 / mm³ secondary to&#xD;
             chemotherapy, corticosteroids greater than 0.5 mg / kg / day for more than 10 days,&#xD;
             HIV seropositivity&#xD;
&#xD;
          -  Severe Acute Asthma&#xD;
&#xD;
          -  Moribund patient or a disease with an estimated survival time of less than three&#xD;
             months&#xD;
&#xD;
          -  Therapeutic limitation Existence&#xD;
&#xD;
          -  minor patient or under guardianship or custody&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  The inclusion of the subject in another biomedical research protocol in progress or&#xD;
             for less than 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric Daubin, MD</last_name>
      <email>daubin-c@chu-caen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

